Gilead Sciences, Inc. (GILD) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Gilead Sciences, Inc. (GILD) Bundle
Engineered for accuracy, our [GILD] DCF Calculator enables you to evaluate Gilead Sciences, Inc. valuation using actual financial data, providing complete flexibility to modify all key parameters for improved forecasts.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22,449.0 | 24,689.0 | 27,305.0 | 27,281.0 | 27,116.0 | 25,725.2 | 24,405.7 | 23,153.9 | 21,966.4 | 20,839.7 |
| Revenue Growth, % | 0 | 9.98 | 10.6 | -0.08789599 | -0.60482 | -5.13 | -5.13 | -5.13 | -5.13 | -5.13 |
| EBITDA | 7,559.0 | 4,133.0 | 11,329.0 | 8,852.0 | 10,496.0 | 8,389.4 | 7,959.1 | 7,550.9 | 7,163.6 | 6,796.2 |
| EBITDA, % | 33.67 | 16.74 | 41.49 | 32.45 | 38.71 | 32.61 | 32.61 | 32.61 | 32.61 | 32.61 |
| Depreciation | 1,404.0 | 1,480.0 | 2,050.0 | 2,103.0 | 2,693.0 | 1,924.1 | 1,825.4 | 1,731.8 | 1,642.9 | 1,558.7 |
| Depreciation, % | 6.25 | 5.99 | 7.51 | 7.71 | 9.93 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 |
| EBIT | 6,155.0 | 2,653.0 | 9,279.0 | 6,749.0 | 7,803.0 | 6,465.3 | 6,133.7 | 5,819.1 | 5,520.6 | 5,237.5 |
| EBIT, % | 27.42 | 10.75 | 33.98 | 24.74 | 28.78 | 25.13 | 25.13 | 25.13 | 25.13 | 25.13 |
| Total Cash | 25,840.0 | 7,910.0 | 7,829.0 | 7,630.0 | 7,264.0 | 11,085.9 | 10,517.3 | 9,977.9 | 9,466.1 | 8,980.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 3,582.0 | 4,892.0 | 4,493.0 | 4,777.0 | 4,660.0 | 4,472.1 | 4,242.8 | 4,025.1 | 3,818.7 | 3,622.8 |
| Account Receivables, % | 15.96 | 19.81 | 16.45 | 17.51 | 17.19 | 17.38 | 17.38 | 17.38 | 17.38 | 17.38 |
| Inventories | 2,067.0 | 3,014.0 | 2,734.0 | 2,820.0 | 1,787.0 | 2,487.9 | 2,360.3 | 2,239.2 | 2,124.4 | 2,015.4 |
| Inventories, % | 9.21 | 12.21 | 10.01 | 10.34 | 6.59 | 9.67 | 9.67 | 9.67 | 9.67 | 9.67 |
| Accounts Payable | 713.0 | 844.0 | 705.0 | 905.0 | 550.0 | 747.2 | 708.9 | 672.5 | 638.0 | 605.3 |
| Accounts Payable, % | 3.18 | 3.42 | 2.58 | 3.32 | 2.03 | 2.9 | 2.9 | 2.9 | 2.9 | 2.9 |
| Capital Expenditure | -825.0 | -650.0 | -579.0 | -728.0 | -585.0 | -681.9 | -647.0 | -613.8 | -582.3 | -552.4 |
| Capital Expenditure, % | -3.67 | -2.63 | -2.12 | -2.67 | -2.16 | -2.65 | -2.65 | -2.65 | -2.65 | -2.65 |
| Tax Rate, % | 17.41 | 17.41 | 17.41 | 17.41 | 17.41 | 17.41 | 17.41 | 17.41 | 17.41 | 17.41 |
| EBITAT | 6,424.6 | 141.5 | 6,977.7 | 5,330.5 | 6,444.7 | 4,423.7 | 4,196.8 | 3,981.5 | 3,777.3 | 3,583.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 2,067.6 | -1,154.5 | 8,988.7 | 6,535.5 | 9,347.7 | 5,349.9 | 5,693.8 | 5,401.8 | 5,124.7 | 4,861.9 |
| WACC, % | 5.23 | 4.5 | 5.04 | 5.07 | 5.09 | 4.98 | 4.98 | 4.98 | 4.98 | 4.98 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 22,961.1 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 5,008 | |||||||||
| Terminal Value | 252,332 | |||||||||
| Present Terminal Value | 197,854 | |||||||||
| Enterprise Value | 220,815 | |||||||||
| Net Debt | 18,902 | |||||||||
| Equity Value | 201,913 | |||||||||
| Diluted Shares Outstanding, MM | 1,258 | |||||||||
| Equity Value Per Share | 160.50 |
What You Will Get
- Real GILD Financial Data: Pre-filled with Gilead Sciences’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Gilead Sciences’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Gilead Sciences, Inc. (GILD).
- WACC Calculator: Comes with a pre-built Weighted Average Cost of Capital sheet featuring customizable inputs specific to GILD.
- Adjustable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates to fit Gilead's financial outlook.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Gilead Sciences, Inc. (GILD).
- Dashboard and Visualizations: Graphical outputs present key valuation metrics for straightforward analysis of GILD.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Gilead Sciences, Inc.'s pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you adjust your assumptions.
- Step 5: Analyze the outputs and leverage the results for investment decisions.
Why Choose This Calculator for Gilead Sciences, Inc. (GILD)?
- Comprehensive Tool: Features DCF, WACC, and financial ratio analyses all in one solution.
- Customizable Inputs: Modify yellow-highlighted cells to explore different scenarios.
- Detailed Insights: Automatically computes Gilead's intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points.
- Professional Quality: Perfect for financial analysts, investors, and business consultants.
Who Should Use Gilead Sciences, Inc. (GILD) Products?
- Healthcare Investors: Make informed investment choices with comprehensive market analysis tools.
- Pharmaceutical Analysts: Streamline your research with detailed reports and data on drug development.
- Consultants: Easily customize presentations for clients focusing on biopharmaceutical strategies.
- Life Sciences Enthusiasts: Enhance your knowledge of biotechnology and pharmaceutical innovations through case studies.
- Educators and Students: Utilize as a resource for real-world applications in healthcare and pharmaceutical education.
What the Template Contains
- Pre-Filled DCF Model: Gilead Sciences’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Gilead’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.